Get the Stockscreener App
1.19
5.26%
0.05
Cumberland Pharmaceuticals Inc stock is traded at $1.19, with a volume of 41,869.
It is up +5.26% in the last 24 hours and down -4.00% over the past month.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
See More
Previous Close:
$1.14
Open:
$1.1
24h Volume:
41,869
Relative Volume:
2.16
Market Cap:
$16.91M
Revenue:
$37.79M
Net Income/Loss:
$-10.38M
P/E Ratio:
-9.1538
EPS:
-0.13
Net Cash Flow:
$-1.00M
1W Performance:
-3.23%
1M Performance:
-4.00%
6M Performance:
-24.05%
1Y Performance:
-40.59%
1-Day Range:
$1.10
$1.21
1-Week Range:
$1.07
$1.33
52-Week Range:
$1.07
$2.3587
Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile
Name
Cumberland Pharmaceuticals Inc
Sector
Phone
615-255-0068
Address
2525 WEST END AVENUE, NASHVILLE,, TN
Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-12 | Reiterated | UBS | Neutral |
| Feb-01-11 | Reiterated | UBS | Neutral |
| Dec-16-10 | Downgrade | UBS | Buy → Neutral |
| Aug-17-10 | Downgrade | Jefferies | Buy → Hold |
| Aug-17-10 | Reiterated | Morgan Joseph | Buy |
| Aug-17-10 | Reiterated | UBS | Buy |
| May-14-10 | Reiterated | Morgan Joseph | Buy |
View All
Cumberland Pharmaceuticals Inc Stock (CPIX) Latest News
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS - Citizentribune
Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight - PR Newswire UK
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt? - Simply Wall St
Cumberland Pharma stock hits 52-week low at $1.18 By Investing.com - Investing.com Australia
Cumberland Pharma stock hits 52-week low at $1.18 - Investing.com India
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size, Share Analysis And Growth Statistics By 2033 - WhaTech
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - India Shorts
Bacterial Pneumonia Market Expected to See Prominent Growth - openPR
Complicated Skin And Skin Structure Infections Drugs Market Insights Discussed Regarding Share, Trends, Siz... - WhaTech
Idiopathic Pulmonary Fibrosis Ipf Market Size and Growth - openPR
Scleroderma Market to Witness Significant Growth by 2031 | Pfizer, Inc., Sanofi, GlaxoSmithKline plc - openPR
Cumberland Pharma stock hits 52-week low at $1.19 By Investing.com - Investing.com Australia
Cumberland Pharma stock hits 52-week low at $1.19 - Investing.com
Vasopressin Market Huge Growth in Future Scope 2024-2031 | Par - openPR
Shareholders have faith in loss-making Phathom Pharmaceuticals (NASDAQ:PHAT) as stock climbs 6.6% in past week, taking one-year gain to 74% - Simply Wall St
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
Cumberland Pharmaceuticals (NASDAQ:CPIX) Research Coverage Started at StockNews.com - Defense World
Scleroderma Diagnostics and Therapeutics Market – 37% of Growth to Originate from APAC -Actelion Pharmaceuticals, Inc., – உங்கள் குரல் - உங்கள் குரல்
Cooling Paste Market Growing Rapidly by-Kobayashi Pharmaceutical, Hisamitsu Pharmaceutical, Pigeon, New Tac Kasei, Sato – IndiaPolitics.com - IndiaPolitics.com
Ibuprofen Injection Industry to Witness Massive Growth (2024-2034) |Cumberland Pharmaceuticals, CSL Limited, Akorn, Inc. – IndiaPolitics.com - IndiaPolitics.com
Cooling Paste Industry to Witness an Outstanding Growth by 2030 |Kobayashi Pharmaceutical, Hisamitsu Pharmaceutical, Pig – IndiaPolitics.com - IndiaPolitics.com
Drugs for Xerostomia Market Future Developments – Concordia, AMICI, Aurobindo Pharma Ltd, Impax Labs - Cauverynews
Burn Pain Market Expected to Experience Major Growth by 2034, - openPR
Burn Pain Market Expected to Experience Major Growth by 2034, According to DelveInsight | Cumberland Pharma, Janssen R&D, Cephalon - Barchart
Nasal Polyposis Drug Market Research Report 2023-2087 - KnowCasino
Scleroderma Global Market Report Detailed by 2024: Forecast And Share 2033 - WhaTech
Global Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsight - GlobeNewswire
Idiopathic Pulmonary Fibrosis Market Forecasted - openPR
Global Asthma Treatment Market to Cross ~USD 32 Billion by 2030 | DelveInsight - GlobeNewswire
Scleroderma Market Size, Share, Growth Insights and Report - openPR
Methotrexate Injection Market Specialized New Report, See - openPR
Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated by Analysts at StockNews.com - Defense World
Autoimmune Treatment Market Growth Analysis with Investment Opportunities For 2024-2033 - EIN News
Cumberland Pharmaceuticals: The first pharma IPO in nearly two years - AOL
Intravenous Ibuprofen Industry Size, Share, Price, Trends, Forecast (2024-2034) - உங்கள் குரல்
Global Inhalable Drugs Market to Register Incremental Growth at a CAGR of ~6% by 2030 | DelveInsight - India Shorts
Hospital Acquired Infection Treatment Market Future Prediction Report By 2030 - openPR
Scleroderma Diagnostics and Therapeutics Market Size, Share, Growth and Industry Trends - Third Eye News
ADT Inc. (NYSE:ADT) Holdings Lowered by XTX Topco Ltd - Defense World
Mira Pharmaceuticals (NASDAQ:MIRA) Stock Quotes, Forecast and News Summary - Benzinga
Cumberland Pharma stock hits 52-week low at $1.2 amid challenges - Investing.com India
Idiopathic Pulmonary Fibrosis Ipf Market Company Profiles, - openPR
Dilated Cardiomyopathy Market to Show Remarkable Growth Trends - openPR
Dilated Cardiomyopathy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Bristol Myers Squibb, Berlin Cures, Cumberland Pharmaceuticals, Vericel Corporation, Corimmun - Barchart
Asthma Market is Predicted to Exhibit Remarkable Growth During - openPR
Battling Superbugs: Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report 2024 - WhaTech
Global mTOR Inhibitors Market Innovations Investigated by Size and Share 2024 - WhaTech
Hepatorenal Syndrome Treatment Global Market Report Explores 2024: Size Forecast and Growth Prospects 2033 - WhaTech
Anthracyclines Market Strategic Insights Growth Path to 2031 - meramandsaur.in
Gardner Syndrome Treatment Market Projected Growth Outlined by Share, Trends, Size, Major Players And Forec... - WhaTech
Methotrexate Injection Market: A Comprehensive Overview - openPR
Cumberland Pharmaceuticals Inc Stock (CPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):